Prime Medicine
PRME
116 hedge funds and large institutions have $266M invested in Prime Medicine in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 18 closing their positions.
816% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $249K
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
0.15% less ownership
Funds ownership: 57.39% → 57.24% (-0.15%)
5% less funds holding
Funds holding: 122 → 116 (-6)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
25% less capital invested
Capital invested by funds: $354M → $266M (-$88.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.02M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$2.87M |
| 3 |
BlackRock
New York
|
+$724K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$700K |
| 5 |
Goldman Sachs
New York
|
+$652K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.51M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.16M |
| 3 |
Two Sigma Investments
New York
|
-$1.68M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$855K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Balyasny Asset Management
Chicago,
Illinois
| – | -$62.2K | -12,101 | Closed |
|
|
SO
127
STRS Ohio
Columbus,
Ohio
| – | -$51.4K | -10,000 | Closed |
|
|
OP
128
ORG Partners
Roanoke,
Indiana
| – | -$28.9K | -5,270 | Closed |
|
|
NC
129
nVerses Capital
Wellington,
Florida
| – | -$18K | -3,500 | Closed |
|
130
Group One Trading
Chicago,
Illinois
| – | -$9.15K | -1,975 | Closed |
|
131
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1.41K | -304 | -93% |
|
132
Lazard Asset Management
New York
| – | -$213 | -46 | -64% |
|
|
C
133
Covestor
London,
United Kingdom
| – | -$5 | -1 | -7% |
|
PRME Hedge Fund Activity: Q3 2024 in Review
116 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q3 2024, worth a combined $266M — down 25% from $354M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PRME and 14 opened new positions — a net loss of 4 holders — while 33 trimmed existing stakes and 39 added.
The largest buyer was Millennium Management, adding an estimated $4.02M. The largest seller was Vanguard Group, cutting an estimated $5.51M.
- 116 institutional investors held Prime Medicine (PRME) as of Q3 2024, down from 122 in Q2 2024.
- Funds reported $266M of Prime Medicine stock for Q3 2024, down 25% quarter-over-quarter.
- 14 funds opened new Prime Medicine positions in Q3 2024 and 18 closed out, a net change of -4 holders.
- The largest Prime Medicine buyer in Q3 2024 was Millennium Management, an estimated $4.02M added.
- The largest Prime Medicine seller in Q3 2024 was Vanguard Group, an estimated $5.51M sold.
Based on aggregated 13F filings for Q3 2024.